(Q40583199)

English

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

scientific article published on April 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

21 September 2017

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). (English)

1 reference

Europe PubMed Central

21 September 2017

multicenter clinical trial

0 references

multiple sclerosis

0 references

6

object named as

Angelo Ghezzi

1 reference

Europe PubMed Central

21 September 2017

author name string

Luca Durelli

1

1 reference

Europe PubMed Central

21 September 2017

Elisabetta Verdun

2

1 reference

Europe PubMed Central

21 September 2017

Pierangelo Barbero

3

1 reference

Europe PubMed Central

21 September 2017

Mauro Bergui

4

1 reference

Europe PubMed Central

21 September 2017

Elisabetta Versino

5

1 reference

Europe PubMed Central

21 September 2017

Enrico Montanari

7

1 reference

Europe PubMed Central

21 September 2017

Mauro Zaffaroni

8

1 reference

Europe PubMed Central

21 September 2017

Independent Comparison of Interferon (INCOMIN) Trial Study Group

9

1 reference

Europe PubMed Central

21 September 2017

language of work or name

0 references

publication date

1 April 2002

1 reference

Europe PubMed Central

21 September 2017

1 reference

Europe PubMed Central

21 September 2017

359

1 reference

Europe PubMed Central

21 September 2017

1453-1460

1 reference

Europe PubMed Central

21 September 2017

9316

1 reference

Europe PubMed Central

21 September 2017

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparative study of the relative bioavailability of different interferon beta preparations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Intra- and inter-observer agreement of brain MRI lesion volume measurements in multiple sclerosis. A comparison of techniques.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

An assessment of clinically useful measures of the consequences of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of interferon beta-1b in MS: assessment of annual accumulation of PD/T2 activity on MRI. UBC MS/MRI Analysis Group and the MS Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Changes in the amount of diseased white matter over time in patients with relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908430-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(02)08430-1

1 reference

Europe PubMed Central

21 September 2017

1 reference

Europe PubMed Central

21 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40583199&oldid=2107697834"